Tags

Type your tag names separated by a space and hit enter

Cholecalciferol supplementation in HIV-infected youth with vitamin D insufficiency: effects on vitamin D status and T-cell phenotype: a randomized controlled trial.
HIV Clin Trials 2013 Mar-Apr; 14(2):51-60HC

Abstract

OBJECTIVES

In addition to its known effects on bone metabolism, vitamin D may regulate immune function.

DESIGN

We performed a randomized controlled trial (RCT) to test whether cholecalciferol supplementation can improve vitamin D status and affect the T-cell phenotype in HIV-infected youth with vitamin D insufficiency.

METHODS

Fifty-two HIV-infected patients aged 8 to 26 years and with serum 25(OH) D <30 ng/mL were randomized to receive orally vitamin D3 100,000 IU or placebo every 3 months for 4 doses. Serum 25(OH)D, 1,25(OH)2D, PTH, and CD4+ T cells were assessed 3 months before baseline and at 0, 3, 6, 9, and 12 months, while Th1-, Th2-, Th17-, and Treg-subsets and T-lymphocyte vitamin D receptor were assessed at 0, 3, and 12 months.

RESULTS

Forty-eight subjects (25 receiving vitamin D and 23 receiving placebo) completed the RCT. Cholecalciferol supplementation produced an early (3 months) decrease in PTH, a concomitant increase in 25(OH)D, and a later (6 months) increase in 1,25(OH)2D levels, all persisting at 12 months. The frequency of vitamin D insufficiency at 12 months was 20% versus 60% in the intervention versus placebo group (P = .007). Cholecalciferol supplementation had no effect on CD4+ T-cell counts but was associated with a decreased Th17:Treg ratio at 3 months.

CONCLUSIONS

In our cohort of HIV-infected youth, a 12-month cholecalciferol supplementation increased 25(OH)D and 1-25(OH)2D and decreased PTH levels but had no effect on CD4+ T-cells. However, it was associated with changes in CD4+ T-cell phenotype, warranting further investigation.

Authors+Show Affiliations

Department of Paediatrics, Luigi Sacco Hospital - Università degli Studi di Milano, Milan, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23611825

Citation

Giacomet, Vania, et al. "Cholecalciferol Supplementation in HIV-infected Youth With Vitamin D Insufficiency: Effects On Vitamin D Status and T-cell Phenotype: a Randomized Controlled Trial." HIV Clinical Trials, vol. 14, no. 2, 2013, pp. 51-60.
Giacomet V, Vigano A, Manfredini V, et al. Cholecalciferol supplementation in HIV-infected youth with vitamin D insufficiency: effects on vitamin D status and T-cell phenotype: a randomized controlled trial. HIV Clin Trials. 2013;14(2):51-60.
Giacomet, V., Vigano, A., Manfredini, V., Cerini, C., Bedogni, G., Mora, S., ... Zuccotti, G. V. (2013). Cholecalciferol supplementation in HIV-infected youth with vitamin D insufficiency: effects on vitamin D status and T-cell phenotype: a randomized controlled trial. HIV Clinical Trials, 14(2), pp. 51-60. doi:10.1310/hct1402-51.
Giacomet V, et al. Cholecalciferol Supplementation in HIV-infected Youth With Vitamin D Insufficiency: Effects On Vitamin D Status and T-cell Phenotype: a Randomized Controlled Trial. HIV Clin Trials. 2013;14(2):51-60. PubMed PMID: 23611825.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cholecalciferol supplementation in HIV-infected youth with vitamin D insufficiency: effects on vitamin D status and T-cell phenotype: a randomized controlled trial. AU - Giacomet,Vania, AU - Vigano,Alessandra, AU - Manfredini,Valeria, AU - Cerini,Chiara, AU - Bedogni,Giorgio, AU - Mora,Stefano, AU - Borelli,Manuela, AU - Trabattoni,Daria, AU - Zuccotti,Gian Vincenzo, PY - 2013/4/25/entrez PY - 2013/4/25/pubmed PY - 2013/6/14/medline SP - 51 EP - 60 JF - HIV clinical trials JO - HIV Clin Trials VL - 14 IS - 2 N2 - OBJECTIVES: In addition to its known effects on bone metabolism, vitamin D may regulate immune function. DESIGN: We performed a randomized controlled trial (RCT) to test whether cholecalciferol supplementation can improve vitamin D status and affect the T-cell phenotype in HIV-infected youth with vitamin D insufficiency. METHODS: Fifty-two HIV-infected patients aged 8 to 26 years and with serum 25(OH) D <30 ng/mL were randomized to receive orally vitamin D3 100,000 IU or placebo every 3 months for 4 doses. Serum 25(OH)D, 1,25(OH)2D, PTH, and CD4+ T cells were assessed 3 months before baseline and at 0, 3, 6, 9, and 12 months, while Th1-, Th2-, Th17-, and Treg-subsets and T-lymphocyte vitamin D receptor were assessed at 0, 3, and 12 months. RESULTS: Forty-eight subjects (25 receiving vitamin D and 23 receiving placebo) completed the RCT. Cholecalciferol supplementation produced an early (3 months) decrease in PTH, a concomitant increase in 25(OH)D, and a later (6 months) increase in 1,25(OH)2D levels, all persisting at 12 months. The frequency of vitamin D insufficiency at 12 months was 20% versus 60% in the intervention versus placebo group (P = .007). Cholecalciferol supplementation had no effect on CD4+ T-cell counts but was associated with a decreased Th17:Treg ratio at 3 months. CONCLUSIONS: In our cohort of HIV-infected youth, a 12-month cholecalciferol supplementation increased 25(OH)D and 1-25(OH)2D and decreased PTH levels but had no effect on CD4+ T-cells. However, it was associated with changes in CD4+ T-cell phenotype, warranting further investigation. SN - 1528-4336 UR - https://www.unboundmedicine.com/medline/citation/23611825/Cholecalciferol_supplementation_in_HIV_infected_youth_with_vitamin_D_insufficiency:_effects_on_vitamin_D_status_and_T_cell_phenotype:_a_randomized_controlled_trial_ L2 - http://www.tandfonline.com/doi/full/10.1310/hct1402-51 DB - PRIME DP - Unbound Medicine ER -